A synthetic lethal approach targeting mutant isocitrate dehydrogenase in acute myeloid leukemia.

Amit Verma, Ulrich Steidl

Abstract readComment

In one paragraph

Article in Nature medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Targeted therapy with a selective BCL-2 inhibitor in older patients with acute myeloid leukemia.Hematology, transfusion and cell therapy
Review

4 · The record

Corrections and comments

Comment on
Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia.2015

5 · Who and what money

Authors and funding

2 authors.

Amit VermaDepartment of Medicine (Oncology), Division of Hemato-Oncology; the Department of Developmental and Molecular Biology; the Ruth L. and David S. Gottesman Institute for Stem Cell and Regenerative Medicine Research; and the Albert Einstein Cancer Center, Albert Einstein College of Medicine/Montefiore Medical Center, New York, New York, USA.

Ulrich SteidlDepartment of Cell Biology; the Department of Medicine (Oncology), Division of Hemato-Oncology; the Ruth L. and David S. Gottesman Institute for Stem Cell and Regenerative Medicine Research; and the Albert Einstein Cancer Center, Albert Einstein College of Medicine/Montefiore Medical Center, New York, New York, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic AgentsBridged Bicyclo Compounds, HeterocyclicDrug Resistance, NeoplasmHumansIsocitrate DehydrogenaseLeukemia, Myeloid, AcuteProto-Oncogene Proteins c-bcl-2SulfonamidesAntineoplastic AgentsBridged Bicyclo Compounds, HeterocyclicIDH1 protein, humanIDH2 protein, humanIsocitrate DehydrogenaseProto-Oncogene Proteins c-bcl-2Sulfonamidesvenetoclax

Identifiers

PMID25654599

DOI10.1038/nm.3796

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.